ArticlePLoS computational biology2015
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.
Article in PLoS computational biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response.Clinical and experimental medicine · 2025Review
- Within- and between-host evolutionary effects on viral oncogenicity.Virus evolution · 2025Article
- Complete genome analysis reveals evolutionary history and temporal dynamics of Marek's disease virus.Frontiers in microbiology · 2022Article
- Quantifying the Evolutionary Constraints and Potential of Hepatitis C Virus NS5A Protein.mSystems · 2021Article
- Resist or perish: Fate of a microbial population subjected to a periodic presence of antimicrobial.PLoS computational biology · 2020Article
- Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.PLoS pathogens · 2019Article
- A Bitter Pill to Swallow: Why Medication Safety Is Critical in Hepatitis C Treatment.P & T : a peer-reviewed journal for formulary management · 2018Article
- Insight into treatment of HIV infection from viral dynamics models.Immunological reviews · 2018Review
- Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Beneficial coinfection can promote within-host viral diversity.Virus evolution · 2018Article
- Why does drug resistance readily evolve but vaccine resistance does not?Proceedings. Biological sciences · 2017Review
- Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?PLoS computational biology · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent discoveries of direct acting antivirals against Hepatitis C virus (HCV) have raised hopes of effective treatment via combination therapies. Yet rapid evolution and high diversity of HCV populations, combined with the reality of suboptimal treatment adherence, make drug resistance a clinical and public health concern. We develop a general model incorporating viral dynamics and pharmacokinetics/ pharmacodynamics to assess how suboptimal adherence affects resistance development and clinical outcomes. We derive design principles and adaptive treatment strategies, identifying a high-risk period when missing doses is particularly risky for de novo resistance, and quantifying the number of additional doses needed to compensate when doses are missed. Using data from large-scale resistance assays, we demonstrate that the risk of resistance can be reduced substantially by applying these principles to a combination therapy of daclatasvir and asunaprevir. By providing a mechanistic framework to link patient characteristics to the risk of resistance, these findings show the potential of rational treatment design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.